2009: Sign-on Letter – Against life + 70 year copyright term in the TPP

Posted on by James Love

This is sign-on letter — Against life + 70 year copyright term in the TPP. See end of letter for details on how to sign.

<-------------------begin letter----------- December 9, 2013 Dear TPP negotiators, In a December 7-10 meeting in Singapore you will be asked to endorse a binding obligation to grant copyright protection for 70 years after the death of an author. We urge you to reject the life + 70 year term for copyright. Continue Reading →

TPP: Senator Hatch to USTR, 12 years of IPR for Biologics test data, no restrictions on cross border data flows

Posted on by James Love

In a December 2, 2013 letter, Senator Orrin Hatch wrote to USTR’s Michael Froman, suggesting TPP exclude any countries that do not meet “high levels of ambition.” According to Hatch, these high ambitions include agreeing to 12 years of exclusive rights for IPR in biologic drug test data, and the elimination of barriers to cross border data flows (a privacy issue). A copy of the Hatch letter is attached below.

The timing of the Hatch letter is designed to pressure countries meeting in Singapore on December 7-10 in the TPP negotiation, on these two contentious issues.

Continue Reading →

Uncategorized

The World Bank definition of “high income” has slipped, in relative terms, compared to high income countries in general

Posted on by James Love

The United States has proposed that some (but no means all) IPR obligations involving medicines be modified for countries with incomes below the amount the World Bank defines as “high.” The threshold to be considered a high income country was $12,616 in per capita income for 2012, and is adjusted every year. In contrast, the US per capita income was $50,124 in 2012. (More data here)

Continue Reading →

Uncategorized

USTR FOIA, 127 pages of emails between industry and USTR TPP negotiators

Posted on by James Love

Earlier this year, IP-Watch submitted two FOIA requests to USTR about the TPP negotiation. I am attaching two letters from USTR to IP-Watch about the FOIAs, and a file with 127 pages of emails between USTR and various industry lobbyists. (USTR provided KEI with copies of the files provdied to IP-Watch as part a separate KEI FOIA to USTR regarding communications involving the TPP).

A lot has clearly been withheld by USTR. According to USTR’s June 19, 2013 letter to IP-Watch

Continue Reading →

KEI proposal for Antibiotics Innovation Funding Mechanism (AIFM), shortlisted for demonstration project by WHO’s EURO region

Posted on by James Love

The WHO is considering potential projects that will demonstrate the feasibility and benefits of open innovation models, delinkage of R&D costs and product prices, and innovative finance mechanisms. The process for selection began at the regional level, as each of six WHO regions was allowed to shortlist four projects that will be considered at a December 3-4, 2013 meeting of experts in Geneva, where the list will be narrowed again, and then considered by the WHO Executive Board in January 2014 and the WHO World Health Assembly in May 2014. Continue Reading →

TPP provisions on Injunctions, are the TRIPS exceptions in or out?

Posted on by James Love

Introduction

This note looks at the TPP, ACTA and TRIPS provisions on injunctions, and finds the TPP text unclear, as regards the possibility of exceptions to the obligation to make injunctions available in cases in of infringements. We have asked USTR and USPTO to clarify this issue.

Discussion

The TRIPS text on injunctions reads as follows:

Section 2: civil and administrative procedures and remedies
Article 44 – Injunctions.

Continue Reading →

Uncategorized